A When the immune system is examined it is usually divided into innate and specific responses. The specific responses have been further divided into humoral and cellular responses. Although these artificial divisions have been very beneficial to study the immune system, it is important to remember that in nature, the response knows no bamers and functions as a single continuous system. The purpose of the immune response is the recognition of selfand response to non-self. This paper will provide an overview of this basic structure and function of the immune system. Immunotoxicology is an applied discipline concerned with: 1) the study of altered immunological responses associated with exposure of humans and animals to xenobiotics, including both agents intended and not intended for therapeutic manipulation; 2) the study of allergy and autoimmunity resulting from exposure to xenobiotics; and, 3) the development of immunological techniques with application for toxicology research and testing. The immune system is a well defined and highly regulated cellular network constituted of thymus-dependent lymphocytes (T cells), bursal-equivalent lymphocytes (B cells) and macrophages. The activation signals, effector mechanisms, and lymphokine products of these cells are now becoming characterized. Dysregulation or functional deficits within this cellular network can result in pathological processes manifested by altered responses to self and nonselfantigens (e.g., allergy and autoimmune disease) or increased susceptibility to infectious agents and neoplasia. For example, it is well established that a large number of diverse xenobiotics or their metabolites possess the capacity to induce allergic responses in susceptible individuals. Similarly, many anticancer drugs and newly developed "biological response modifiers" possess the capacity to modulate immunological responsiveness. Additionally, several chemicals of occupational or environmental concern which have produced immune modification in rodents are suspect of producing similar effects in humans, although in most examples. rigorous clinical confirmation of immunological responsiveness is often incomplete. Considering the continuing requirements for cell renewal, differentiation and activation within this organ system, it is easily understood that the immune system may be a frequent target organ for toxicity. During the past several years clinically relevant methods have been developed and validated in rodent models to assess xenobiotic-induced dysfunction in the humoral or cellmediated immune component. An interlaboratory comparison of these methods was utilized for methods selection. With rigor and appropriate quality control procedures, these methods have been applied during preclinical or prerelease development to evaluate the immunoalterative potential of suspect xenobiotics. Quantitative data are being developed which allow correlation between immune dysfunction and altered susceptibility to challenge with infectious agents (e.g., viral, bacterial, and parasitic) and transplantable tumor cells. These data demonstrate correlation between alterations in certain functional parameters and resistance (e.g., effect threshold) to specific challenge agents. More quantitative data are needed to establish the precise threshold for altered host resistance for each 'immune alteration measured and to facilitate the use of these data in safety assessment.
Mechanisms of Xenobiotic-Induced Immune Alterations F. SPREAFICO, The Mario Negri Institute of Pharmacological Research, Milan, 'Italy i Since immunomodulatory drugs can be regarded as prototypic immunotoxic xenobiotics, in the first part of this talk I shall concentrate on the heterogeneity of the immune effects exerted by such compounds. Thus examples will be given of the possibility that a compound may differentially affect immune cells not only belonging to different lineages but also belonging to different subsets of the same population. Examples will then be given of the possibility that this differential sensitivity to exogenous modulation may extend to cells of the same type but residing in different anatomical, locales, and to different functional activities sustained by the same cell, thus resulting in non-stereotypic immunological profiles even among close structural analogs. The fact that dosekelated differences in sensitiidy among cells may result in paradoxical effects and the mechanisms sustaining such effects will then be discussed, together with examples of the possibility that xenobiotip may also reveal similar complex modes ofaction at the immune cell level. Employing selected examples with various xenobiotics, several possible subcellulai mechanisms thai may be involved in immune cell damage will then be illus- Autoimmunity is usually defined as the body's immune system turning against itself to generate destructive immune mechanisms often leading to pathology and autoimmune disease. At least four major factors (genetic, viral, sex hormonal, and psychoneuroimmunologic) play a role in the pathogenesis of autoimmune diseases. The precise contributions ofthese factors will be discussed. All ofthese influences act upon the immunoregulatory system to create a state of disordered immunoregulation which forms the basis for autoimmunity. Studies in experimental animals and in patients over the last two decades have contributed greatly to our understanding of the etiology and pathogenesis of autoimmune diseases. Specific mechanisms underlying the immunopathologic events in autoimmunity will be presented, including the inter-relationships between various subpopulations of lymphocytes, the role of antigen presenting cells, the function of interleukin 1 and interleukin 2 in normal and abnormal immunologic responses, and the contributions of interferon and natural killer cells. In the last few years, studies on idiotypic regulation and molecular genetics have offered new and in some cases surprising insights into the problem of autoimmunity. These will be briefly summarized, particularly with regard to the role of cross reactivity and perturbed idiotype networks as contributors to autoimmune disease.
Mechanisms of Hypersensitivity R. PATTERSON, Northwestern University, Chicago, Illinois Immunologic mechanisms of hypersensitivity are best discussed using the Gel1 and Coombs classification. This classification describes the four major types of hypersensitivity. Type I Anaphylactic or Immediate Type: This IgE mediated reaction results in allergic rhinitis, asthma or anaphylaxis. The Type I1 reaction is cytotoxic in which the antigen is a component of a cell surface and antibody reacts with the cell surface antigen and the cell. Type I11 is the toxic antigen-antibody complex reaction in which the complex plus complement attracts leukocytes and the release of leukocyte inflammatory mediators results in tissue damage. Type IV is lymphocyte mediated in which lymphocytes with specificity against antigens or cells recruit additional lymphocytes in a delayed tuberculin type reaction. All of these types of hypersensitivity may result from foreign proteins or may result from simple chemicals which serve as haptens. In the best understood human reactions, the reactive chemical forms a chemical (C)-self protein complex (SPC) with new antigenic determinants (NADs). The C-SPC-NADs can immunize the host. On subsequent re-exposure to the reactive chemical, the C-SPC-NADs reacts with the specific antibodies or lymphocytes to produce the type or types of hypersensitivity reactions described above. The description of four human respiratory syndromes due to trimellitic anhydride, three of them immunologically mediated, offers a model for hypersensitivity reactions against inhaled chemicals.
In vivo/In vitro Methods
S. KFMKOWKA, The Ohio State University, Columbus, Ohio Interaction between environmental and administered toxicants and the immune system are complex and effects can vary with the chemical nature of the substances, dose, route of exposure and metabolism of the materials. Host factors include species differences, age, gender, genetic strain and physiological state. Modulation of immunity is likely dose-dependent and can be immediately delayed or manifest only as a synergistic interaction with a second agent, living or inanimate. In this regard, the conceptual problem faced by immunotoxicologists has two aspects to it: design and implementation of screening procedures which will identify immunotoxicants without significant false negative results and; correlation and extrapolation of findings to the anticipated leveVdose of the substance under study. A multi-tiered approach to assessment is probably the ideal mechanism for evaluation. General evaluation should include physical appearance, determination of lifespan and reproductive capacity, alterations in susceptibility to disease causing potential of both commensal and pathogenic infectious agents within the colony and careful determinations of changes in background or spontaneous tumor incidence. Gross and histopathologic examinations of tissues are an essential component of the process. In addition to generation of routine hematology profiles, primary (e.g., thymus and bone marrow) and secondary (e.g., lymph nodes and spleen) should be examined. In the latter, attention should be directed to microscopic evaluation of T-cell dependent and B-cell dependent regions for the following general categories of relative change: increase in cellularity (hyperplasia), decrease in cellularity (depletion) or no changes from the normal. Coincident with this phase, a judgment should be made regarding the effects of the substance upon nonlymphoid organ systems. Primary damage to an unrelated organ such as the liver may produce secondary, biologically significant changes in immunity. If the goal of the screening process is to identify primary immunotoxicants, then the dose/exposure regimen must either be adjusted so that nonlymphoid tissues are morphological and biochemically normal or consideration must be given to the use of analogue chemicals which spare nonlymphoid organs. Assuming that a primary immunotoxicant effect is identified, then further evaluation is warranted. In vivo, passive assessment should include: hematology (an indirect measure of bone marrow colony-forming unit-stem cell, myeloid and erythroid capacity), quantitation of serum immunoglobulin levels by radial immunodiffusion, quantitation of circulating lymphocyte subsets via cytofluorometry with subset-specific antisera and complement titrations (CHso or CHI, methods). In vivo active assessment for B cell, T cell and macrophage functions is accomplished via response to immunization with bacterial LPS (B cell), skin test reactivity or allograft rejection (T cell) and carbon clearance (macrophage) assays. In vitro tests useful in identifying deficits in immunity include: lectin responsiveness (general), response to LPS or pokeweed mitogen (B cells) helper, suppressor and cytotoxic assays (T cells), natural killer cell cytotoxicity assay (NK cells), and phagocytosiskilling of s. aureus, Candidu sp. (macrophages). From this, the site(s) of deficiency will be apparent. At this point, if warranted, additional in vitro assays can be employed to further define the nature of the problem with the eventual goal of circumvention or realistic risk assessment.
Assessment of Hypersensitivity B. 0. BROOKS, Health Effects Research, IBM Corporation, Boulder, Colorado Hypersensitivity is one of the most visible yet difficult areas of interest within the emerging field of immunotoxicology. Chronic, low level occupationallenvironmental exposure to a vast milieu of chemicals produces a perplexing array of hypersensitivity disorders in today's worker. Assessment of true immunologically based hypersensitivity involves both diagnostic and prognostic/preventive approaches. Much knowledge gained through basic immunology research can now be applied to actual workplace/environmental issues. The use of standard and "horizon" techniques enhances our ability to not only diagnose the etiologic agent(s) of hypersensitivity but also to eliminate their adverse usage in commercial products and processes. Practical analysis of hypersensitivity due to ethylenediamine (EDA) exposure serves as a paradigm of this subset of immunotoxicology. Ethylenediamine is a potent imtant and sensitizer via dermal or pulmonary routes of exposure. Sensitization to EDA produces an array of clinically distinct syndromes. Occupational exposures below the current Threshold Limit Value (TLV) for EDA have produced sensitization in humans. Experimental evidence collected from animal models suggests that assays developed in our laboratories and others can detect EDA-induced alterations in both humoral and cellular immunity. Possible applications/limitations of immunoassay technology are discussed with respect to preventive aspects of sensitization due to occupationallenvironmental exposure to chemicals. The advantages of quick and easy quantitative bioassays are obvious. These bioassays will be meaningful to the pathologist if they are correlated with morphologic pathogenesis. We established such a correlation for oxazolone-induced allergic contact dermatitis in mice. This in vivo model has been used for identifying potential anti-inflammatory and immune-modulating drugs. Studies were conducted with this model to detail the histokinetics of the inflammatory response and to examine the adequacy of three assays for measuring the intensity of the inflammatory response when compared to histologic findings. CD-1 mice were sensitized with oxazolone on the flank and challenged on the dorsum of the ear pinna. The inflammatory response was quantitated by measuring the change in pinna weight and thickness and presence of lZsI-2 deoxyuridine (lZJIUDR)-labeled cells. Cellular infiltrate was mixed with general predominance of mononuclear cells over neutrophils. Correlation with the histologic data suggests that both the ear weight and thickness assays are suitable primary screening assays, since both provided a sensitive, accurate and objective measure of the inflammatory response and its suppression of dexamethasone. The 12SIUDR assay worked well in untreated mice but was unsatisfactory in mice treated topically or systemically with dexamethasone. TOXICOLOGIC PATHOLOGY Immunotoxicology: A Contract Laboratory's Experience P. THOMAS, IIT Research Institute, Chicago, 11-linois As more is learned about the immune system's role in homeostasis, increasing emphasis is being placed on its role as a target organ for toxicity and on its manipulation using immunotherapy, IITRI has been conducting immunotoxicology studies since the 1950s when EPA-funded research began on air pollution and susceptibility to pulmonary infection. We recently were involved in an NIEHSlNational Toxicology Program (NTP)-sponsored interlaboratory validation exercise to develop a battery of tests useful for making immunomodulation profiles of chemical xenobiotics. Currently there are no regulatory testing requirements for immunotoxicology. However, the EPA has issued guidelines for collection of immunology data on biochemical pesticides (Subpart M). In spite of no mandatory testing requirements, there is considerable activity in this area. Industry is sponsoring studies at IITRI: 1) for immunotherapy drug development, 2) to increase health and safety data base of proprietary compounds, 3) because of past litigation, and 4) for regulatory purposes. The industry sector includes chemical and pesticide manufacturers, pharmaceutical companies and the federal government (NTP). They have selected IITRI because: 1) it is an independent laboratory, 2) we have experience with the "NTP-approved" immunotoxicology testing battery, 3) we adhere to all quality assurance/ GLP guidelines. Xenobiotics J. C. BLoohi, Smith Kline & French Laboratories, Philadelphia, Pennsylvania Investigating the immunotoxic potential of candidate compounds for drug development poses several practical problems. These include a limited understanding of the immune system; the lack of practical, validated techniques for assessing immune function as a potential target organ system; the inability to clearly establish the biologic (toxicologic) significance of results of in vifro and ex-vivo immune function assays; and a poor understanding of the predictive value of laboratory observations in our animal models for iatrogenic immune dysfunction in man. Scientists in research and development organizations within the pharmaceutical industry are uniquely positioned to deal with these problems. The substantial resources of the industry include expertise in basic immunology and immunopathology, as well as facilities, funds and a priority to address these issues. More importantly, however, is access to information on candidate drugs which includes molecular and cell biology, pharmacology, drug metabolism, toxicity and safety studies and, eventually, results of clinical investigations in man. This provides the essential context that allows meaningful interpretation of laboratory observations on immune function and immunopathology. A key component of this context is the toxicologic profile we generate through our acute, subacute and chronic toxicity and safety studies. As this assessment becomes increasingly comprehensive and sophisticated, toxicologically significant drug-associated changes in immune function are, arguably, reflected in the results of these "routine" studies, in most cases. Such findings serve as "triggers" for conducting investigations of possible immune mechanisms. Examples of such triggers and follow-up investigations will be discussed in this presentation. In conclusion, we are presently poorly equipped to effectively screen drugs indiscriminately for an immunotoxic potential. We are better prepared, however, as toxicologic pathologists, to address the question of whether a drug-associated change is due to an adverse effect on the immune system. This problem-oriented approach to immunotoxicology challenges us as diagnosticians and immunopathologists and requires a close working relationship among the toxicologic pathologist, the basic immunologist, the immunopharmacologist, and the clinician.
Environmental Chemicals J. G. Vos, National Institute of Public Health and
Environmental Hygiene, Bilthoven, The Nethe r 1 and s In order to assess the immunotoxicity of a chemical, morphological examination of the lymphoid system is of great value. A thorough study of the immune system should include histopathology of the thymus, bone marrow, spleen, lymph nodes and mucosa-associated lymphoid tissues. Routine histopathology, which depends mostly on hematoxylin and eosin staining, has been shown in many studies to be quite useful, in particular when these data were combined with effects on weights of the lymphoid organs. Because of the structural division of peripheral lymphoid tissues into thymus-dependent and thymus-independent areas, morphology can give an indication regarding the effect on T o r B lymphocyte compartments. For in depth investigation ofthe immune system, immune histochemistry is a powerful tool. In particular the recent progress in the development of immunoperoxidase techniques and the availability of monoclonal antibodies have enabled the identification of lymphoid subpopulations in tissue sections. Examples will be presented of environmental chemicals causing immune suppression or immune stimulation, as identified by these morphological procedures.
Immune Responses in the Central Nervous System
D. E. GRIFFIN, The Johns Hopkins University School of Medicine, Baltimore, Maryland Immune responses occumng within the central nervous system (CNS) have unique features attributable to the cellular and functional organization of the CNS and to the presence of the blood brain bamer which restricts movement of immunologically important cells and proteins from the blood into the CNS. Normal immune responses to infection within the C N S involve the participation of most immunologically important cells: T and B lymphocytes, monocytes and natural killer cells. Helperiinducer-type T lymphocytes are the earliest identifiable cells to appear. After stimulation with the relevant antigen in tissue, these cells are hypothesized to produce lymphokines which stimulate local mast cells to open capillary tight junctions, stimulate proliferation of lymphocytes locally, and which attract monocytes and B lymphocytes into the developing inflammatory response. In acute reactions cytotoxic/suppressor T lymphocytes are relatively infrequent, but if the antigen is not cleared and the inflammatory process becomes chronic these cells appear to increase in number. B lymphocytes mature into immunoglobulin-producing cells which secrete antibody locally which appears in the cerebrospinal fluid. In other situations the immune response appears to target normal CNS tissue rather than foreign antigens. Two general types ofreactions may be seen: (1) vasculitis with destruction ofvessel walls and infarction and (2) perivascular inflammation with demyelination. The former may be associated with immune complex deposition and the cellular infiltrate included polymorphonuclear leukocytes. Immune complex deposition may also cause disease in the choroid plexus which shares many properties with the glomerulus. The inflammation associated with perivenular demyelination is composed almost exclusively of mononuclear leukocytes. In the diseases for which pathogenetic mechanisms are understood cells become sensitized to myelin constituents (usually myelin basic protein, but galactocerebrosides and proteolipids have also been implicated as antigens) and induce local demyelinating lesions in which the damage is effected by macrophages, it is not clear whether macrophages are directed in this destructive effort by lymphokines or immunoglobulins or both. Recent advances in'immunocytochemical techniques allow the localization of specific antigens in tissue sections. The work reported here attempts to evaluate the application of antibody-labelled, disease-related protein, followed by microscopy and computerized image analysis. Using an experimental anti-tumor, polyclonal antibody (anti-oncomodulin) as a model, various tissues were prepared for light microscope immunocytochemistry. Sections were incubated with primary antibody, then biotinylated secondary antibody. This was followed by incubation with avidin-biotin peroxidase (ABC method). Marker was visualized by the presence of precipitated diaminobenzidine. Photomicrographs were made and samples evaluated using a Zeiss/ Kontron IBAS I & I1 semi-automatic digital image analysis system. Statistical analyses were performed on output data. Results demonstrated a precise localization and volume density determination of immunolabel. Statistical comparisons showed significant differences between control and experimental sections. The practical application of these combined techniques provides the toxicologic pathologist with a powerful tool for accurate and objective determination of the location and relative amount ofselected proteins in normal and abnormal tissues. Trichothecene mycotoxins, particularly T-2 toxin, have recently been implicated as chemical warfare agents in "Yellow Rain" used in southeast Asia and Afghanistan. Since inhalation is one ofthe most important routes of exposure to such an agent, we examined the effect of inhaled T-2 toxin on pulmonary immunity and morphology ofthe lungs and other organs. Thirty-four, 9-to 1 l-week-old, male castrated, crossbred, specific pat hogen-free derived pigs were exposed to an aerosol of T-2 toxin at a nebulized dose of 0 or 9 mpjkg in pairs, each pair consisting of one control and one T-2 treated pig which were exposed on the same day. Twenty to 30 Dercent of the T-2 toxin. 1.8 to 2.7 mdke. waq rew. M. HASCHEK-HOCK, v. PANG, R. LAMBERT, P. TOXICOLOGIC PATHOLOGY tained by the pigs. Five pairs of pigs were killed on each of 1, 3 and 7 days after dosing. Since one T-2 treated pig died and another was killed in a moribund state at 8 to 10 hours after dosing, a 0.33-day group was also designated, and paired controls were killed at this time. Alveolar macrophages (AM) and pulmonary lymphocytes (PL) were obtained by bronchoalveolar lavage. The phagocytic ability of AM and mitogen-induced blastogenic responses of enriched PL were evaluated. Representative tissues were examined histologically. All of the T-2 treated pigs vomited and became cyanotic, anorexic, lethargic and laterally recumbent. There was a marked reduction in AM phagocytosis and mitogen-induced blastogenic responses of PL in T-2 treated pigs from the 0.33-, 1-and 3-day groups. Mild, multifocal interstitial pneumonia was seen in the majority of the T-2 treated pigs. Pigs dying following inhalation of T-2 toxin had more severe pneumonia as well as marked necrosis of lymphoid tissues, severe necrohemorrhagic gastroenteritis, and multifocal necrosis of the heart and pancreas. Thus, inhalation exposure to T-2 toxin can be lethal, with clinical signs and morphologic changes similar to those reported previously in pigs given T-2 toxin iv at a dose of 1.2 mg/kg (LD,,) or greater. In pigs surviving inhalation exposure, there is transient impairment of pulmonary immunity and mild tissue injury.
T-2 Toxicosis in Swine Following
Imrnunopharmacologic Bases of Immunotherapy J. W. HADDEN, Program of Immunopharmacology, University of South Florida College of Medicine, Tampa, Florida Secondary immune deficiency generally involves more profound defects in cellular than humoral immunity. This type of immune deficiency occurs in acquired immunodeficiency syndrome (AIDS), cancer, malnutrition, aging and following immunosuppressive therapy and immunotoxicant exposure. Immunorestorative therapies were developed for use in the immunotherapy of cancer. Their experimental use in cancer and other diseases such as infections and autoimmunity has demonstrated their safety and their capacity to improve host responses to disease particularly when the host is immunocompromised. Rational pharmacological cell modulation of T cell ontogeny depends upon a complete understanding of the natural mechanisms controlling these processes. At the present time this understanding is deficient; however, recent information has contributed considerable insight. The precursor of the T lymphocyte (prothymocyte) resides in hematopoietic tissues such as bone marrow and spleen in the mouse and can be induced to display intrathymic markers like Thy 1 or 0 by thymic hormones such as thymosin fraction V, a l , thymulin, or thymopoietin. The prothymocyte can also be induced to mature by interleukin (IL) I1 but not IL-1. Their proliferation is also dependent on IL-11. The bulk of intrathymic lymphocytes are immature and nonfunctional. These cells can be induced to become functionally mature by IL-I1 but not the thymic hormones or IL-1. Mature T cells are modulated by thymic hormones and IL-1 to produce IL-11 and are responsive to mitogens and antigens. Attempts to recapitulate T cell ontogeny with thymic hormones has only been partially successful. Recent work indicates that thymic hormones combined with IL-I1 may be more successful. Two classes of thymomimetic drugs have been developed for treatment of secondary T cell-related immunodeficiencies. Purines, such as isoprinosine and NPT 15392, induce prothymocyte differentiation and regulate various T cell functions in vifro and in vivo. Their actions have translated into immunorestoration in disorders such as cancer, viral infections and autoimmunity. Sulfur-containing compounds, such as levamisole and imuthiol (DTC), induce prothymocyte maturation and modulate T cell functions in vivo but not in vitro. This action is thought to be mediated by a thymic hormone-like factor from liver. These actions have also contributed to therapeutic immunorestoration in experimental and clinical studies. The prospects for therapeutic manipulation of T cell ontogeny as well as of the function of mature T cells is currently greatly enhanced through an increased understanding of the immunopharmacologies of the thymic hormones, interleukins, and the thymomimetic drugs. The clinical application of these agents in primary and secondary immunodeficiency associated with AIDS, cancer, aging, acute and chronic infection and autoimmunity is an active area of experimental clinical therapeutics.
Interleukin-1 and Interferon-7: Cytokines that Provide Reciprocal Regulation of Macrophage and T-cell Function R. M. SCHULTZ, Lilly Research Laboratories, Indianapolis, Indiana Interactions between macrophages and T-cells are symbiotic in nature, since optimal function of both cell types requires interchange of soluble mediators. Upon activation, macrophages release interleukin-1 (alias lymphocyte-activating factor, leukocytic endogenous mediator, and endogenous pyrogen), a family of molecules with multivarious biological effects, ranging from induction of fever and the acute phase response to lymphocyte activation and concomitant release ofinterleukin-2. Both interleukin-2 and leukotrienes enhance production of immune interferon (interferon-y) by activated T-cells. Aside Vol. 14, No. 2, 1986 from antiviral activity, interferon-y produces a number of immunomodulatory effects, including macrophage activation (Ia induction, microbial effector function, and activation of oxidative metabolism) and augmentation of NK function. Expression of Ia on accessory cell membranes is required for the initiation of many antigen-specific, T-dependent immune responses. Interferon-y also synergizes with a variety of microbial agents to augment macrophage tumoricidal function and enhance IG 1 secretion. The production of interferon-y appears to have a critical role in feeding back the cascade of interleukins in a loop of amplification. Both interleukin-I and interferon-y modulate release of arachidonate metabolites in various cells. This cascade of cytokines in collaboration with arachidonate oxygenation products regulate immunity and set the stage for many of the events underlying inflammation. The ability of various anti-inflammatory drugs and immunopotentiators to modulate cytokine pathways is discussed.
Mechanisms of Immunomodulation by Drugs
1.-J. LEBISH, American Cyanamid Co., Pearl River, New York Immunomodulators are those intrinsic or extrinsic substances which regulate or alter the scope, type, duration or competency of the immune response. Antigen stimulation yields a complex interaction between immunologically active cells. Specific antibody synthesis and active effector cells are produced. The nature, magnitude and specific form is determined by an array of modulatory processes which orchestrate this response. Multiple pathways of regulation are used by the competent immune system depending on the appropriate response required. Perturbations or incompetency of almost any aspect of this response can produce serious consequences for the organism. In recent years it has been well recognized that many diseases which have immune-mediated factors can be modified by the administration of biologicals or chemicals which activate or suppress key pathways in the immune system. The search for anticancer chemotherapeutic agents which have less toxicity for normal tissues has led to exploration for substances which alter the immune response to the tumor. In addition, the rapid dissemination of infectious diseases which produce severe immunosuppression has intensified the search for substances which are capable of restoring the immune response. The search for less toxic cancer chemotherapeutic agents has led to the screening of biological response modifiers (BRM). These substances modify the relationship between the tumor and host by altering the host's biological response to the tumor. They can modify responses in several ways: a) augmentation and/or restoration of effector mechanisms or mediators of host defense; b) decrease the deleterious component of the host's reaction; c) replace the damaged effector or mediator mechanisms with natural biologics or synthetic derivatives; d) augment the host response to vaccines and chemotherapeutic agents; e) decrease transformation and/or increase differentiation of tumor cells; f) increase the ability of the host to tolerate damage by cytotoxic modalities. The emphasis in the presentation will be placed on those synthetic substances which have immunomodulating properties. These substances may produce their effects by the following general mechanisms: 1) effect on antigen immunogenicity, distribution, persistence, presentation and processing; 2) effect on production and differentiation of precursor immunocytes; 3) effect on traffic and/or threshold levels for activation-inactivation of mature effector and regulatory immunocytes; 4) effect on production, release, metabolism of effector or intercellular regulatory mechanisms; 5 ) effect on number, localization, functional activity or other cells (e.g., neutrophils) and connected humoral mechanisms; 6 ) effect on non-immunological modulatory circuits (e.g., hormonal homeostasis). The possible mechanisms of actions of a number of synthetic substances will be discussed. Emphasis will be placed on the mechanisms of action of an acridine compound which has immunomodulating properties. This low molecular weight compound is an immunomodulator and anticancer adjuvant which has been shown to induce high levels of circulating interferon in mice, protect mice against lethal viral infection, stimulate macrophage and NK cell cytotoxicity for tumor cells, partially restore humoral and cellular immune responses in tumor bearing, immunosuppressed mice, and augment the cytotoxic, T-lymphocyte response to syngeneic tumor cells. In addition, it has exhibited moderate, direct inhibitory effects on the growth of solid tumors in mice, as well as substantial antimetastatic adjuvant tumor activity with surgery and chemotherapy.
Pathologist's Role in Assessing Immunotoxicity
H. E. BLACK, Schering Corporation, Lafayette, New Jersey The complex and dynamic immune system may be intentionally manipulated or unexpectedly altered by chemical agents. The toxicologic pathologist is in a unique position to identify and describe the end organ changes that may reflect these effects. Early deaths, an increased incidence of disease, the early appearance of tumors and changes in the
